Between May 1994 and May 2000, we autotransplanted 48 consecutive patients, 21 females and 27 males aged over 60 years (range: 60-78, median: 63). Sixteen patients had multiple myeloma (MM), 14 high-grade non-Hodgkin's lymphoma (HGNHL), six low-grade non-Hodgkin's lymphoma (LGNHL), nine acute myeloid leukemia (AML), one chronic lymphocytic leukemia (CLL), one Hodgkin's disease (HD) and one breast cancer; the performance status (WHO) was 0-1. Seventeen patients were in 1st CR (35.4%) and one in 2nd CR (2.1%), 25 in PR (52.1%), while five patients had been transplanted with progressive disease (10.4%); seven patients with MM received a double transplant. Patients received high-dose therapy including melphalan alone (13) or associated with other drugs (26), busulfan-cyclophosphamide (three), BEAM (11) and TBI (two). All patients took a median of 11 (range: 8-25) days to reach neutrophils Ͼ500/l, 13 (range: 9-83) days to reach platelets Ͼ20 000/l and 17 (range: 11-83) days to reach platelets Ͼ50 000/l. Hematological toxicity, hospital stay and supportive care did not differ from those of a cohort of younger patients. At present, 31 patients are alive (14 in CR, five in PR, five in PD and seven in relapse) and 16 died from PD at a median follow-up of 37 months (1-67). Only one patient died from transplant-related toxicity. Quality of life, evaluated using a QLQ-C30 questionnaire in 25 patients at day +90, was good. In our experience PBPC mobilization and transplantation is feasible in patients aged у60 years and the toxicity of this procedure is acceptable, with an early transplant-related mortality of 1.8%; therefore patients with hematological malignancies potentially curable with high-dose therapy (HDT) should also be candidates for HDT. Bone Marrow Transplantation (2001) 27, 1189-1195.
High-dose therapy (HDT) with ASCT (autologous stem cell transplant) may be considered the treatment of choice for many hematological malignancies including intermediatehigh grade NHL relapsing after primary therapy, 1 and MM. It may be used as first-line treatment with single or double auto-transplantation. 2 In patients with low-grade NHL 3 and HD, 4 HDT with ASCT has also been proven to cure or prolong survival after failure of primary CHT.
Finally, in ANLL and in many chemosensitive solid tumors, HDT with ASCT has proved to be at least as good as the best chemotherapy (CHT). 5, 6 Extrahematological toxicity, performance status and age represent the main hurdles in using HDT in elderly patients. To date, very few reports concerning the use of HDT in elderly patients have been published [7] [8] [9] and ASCT is usually restricted in many centers to patients aged less than 50 or 60 years. An EBMT survey reports transplant-related mortality 13% (TRM) in patients aged 55 years and over, transplanted for intermediate-high grade NHL, 10 but more recent data suggest that in the same setting, very low TRM can be achieved, using mobilized PBSC and conditioning regimens not including TBI. [7] [8] [9] Here, we report our single center experience in 48 patients aged Ͼ60 years (33% of these aged Ͼ65 years), autotransplanted with PBSC for hematological malignancies.
Patients and methods

Patients
Between May 1994 and May 2000, we transplanted 48 patients aged more than 60 years (range 60-78 years; median 63 years), 21 females and 27 males. Patients were eligible for HDT when performance status (PS WHO score) was good (0-1) and no relevant comorbidities were present, such as cardiac or respiratory failure, severe liver or renal disease or diabetes. ASCT was performed when a sufficient dose of CD34 + cells (Ͼ2.5 ϫ 10 6 /kg) was recovered. The main patient characteristics are listed in Table 1 .
The disease status before transplant was different, according to the underlying disease: 17 patients were in 1st complete remission (CR) (35.4%) and one in 2nd CR (Table 2) . Table 3 shows the different priming chemotherapy regimens used. G-CSF was administered at a dose of 5-10 g/kg, from the end of the chemotherapy until the last leukapheresis. Leukapheresis started when the circulating CD34 + cell count was Ͼ20/l, beginning on average on day +13 after the end of priming CHT (range [11] [12] [13] [14] [15] [16] [17] [18] . Aphereses were carried out using an automated blood cell separator Fenwall CS 3000 Plus (Baxter, Deerfield, IL, USA), with a 50 ml/min flow rate, according to modified program 1 for lymphocyto-apheresis; as previously described the total volume processed ranged from 7 to 11 liters (median 10) and a final volume of 50 ml was collected using the Baxter small volume chamber. The final product was cryopreserved in 10% DMSO plus 4% human serum albumin (HSA) after uncontrolled rate freezing, placing the bags directly into a mechanical freezing device at −80°C as previously described.
Priming and collections
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A median of 1.9 ϫ 10 8 (0.3-13.7) MNC/kg, 5.9 ϫ 10 6 (2.7-16.5) CD34 + /kg and 67 (0-315) × 10 4 CFU-GM/kg were collected with a median of 2 (range, 1-4) leukaphereses.
Conditioning regimens and patient care
We performed 55 HDT (double HDT in seven patients with MM) on 48 patients; HDT regimens included high-dose melphalan (HDM) in 50 procedures (dose ranging from 120-180 mg/m 2 in combination with other drugs, to 200 mg/m 2 as single agent), Bu-Cy in three patients, and TBI in two patients (for details see Table 4 ).
In 25/48 (52%) patients, HDM was preceded by the infusion of amifostine as previously reported. 12 
Patient care and quality of life evaluation
Central venous catheters (CVC) were placed in all patients prior to HDT, and CVC care was given according to Hospital Infection Control Practices Advisory Committee guidelines.
Starting on the 5th day after PBPC reinfusion, all patients received G-CSF 5 g/kg/day until the WBC count reached 5000/l; irradiated blood products were infused to maintain hemoglobin and platelet levels (PLT) above 8 g/dl and 10 000/l, respectively.
Mouth care, antimicrobial prophylaxis and febrile episode treatment were given as previously described. 13 When severe mucositis (III-IV) was present, patients received analgesia with morphine by continuous i.v. infusion. When mucositis was associated with severe diarrhea or emesis with electrolyte disorders and significant weight loss, total parenteral nutrition (TPN) was also given.
Hematological and extrahematological toxicities were evaluated using the NCIC-CTG grading.
14 Before transplantation and between day +30 and +60, patients were evaluated for cardiac function (left ventricular ejection fraction, LVEF) using echocardiography or radionuclide ventriculography, respiratory function evaluating respiratory volumes (flow expiratory volume 1 (FEV1), flow volume capacity (FVC) and the FEV1/FVC ratio) and COLD (CO lung diffusion), [15] [16] [17] immune reconstitution, and bone marrow examination.
Evaluation of quality of life was carried out in 25 patients, who gave their consent, by using the EORTC Quality of Life questionnaire (QLQ-C30). [18] [19] [20] The questionnaire consists of 30 items measuring functional scales including physical, role, cognitive, social, global health and emotional functions and symptom scales including appetite loss, sleeplessness, dyspnea, constipation, diarrhea and the perceived financial impact. Item scores are linearly transfomed to a 0-100 point scale along EORTC criteria. A higher score represented a better level on the functional scale. A reversed code was used for symptom scales, since a higher score corresponded to a higher level of symptoms; in this case the lowest score corresponded to a better quality of life. The QLQ-C30 was answered at day +90 after autotransplant.
Response criteria and statistical analysis
Pre-and post-transplant disease status were assessed according to WHO/ECOG standard guidelines in lymphoma patients. 21 Residual disease was assessed by CT scan and bone marrow biopsy at 8-12 weeks after transplant, every 3 months for the first year and every 6 months until the second year. In patients with multiple myeloma the ECOG criteria were used.
Survival was calculated from the day of transplant to death, and progression-free survival from the day of transplant until the date of progression or death.
Descriptive analyses were performed to quantify hematological and extrahematological toxicity occurring within day +30 post-transplant.
The Mann-Whitney U or Wilcoxon test were applied for continuous variables and the Chi-square or the Fisher's exact test were performed to analyze discrete variables. We previously reported that hematological recovery mainly depends on the number of CD34 + cells infused. 22 We therefore analyzed the level of CD34 + cells infused, the incidence and severity of hematological toxicity, duration of TPN and ATB therapy, duration of fever and hospitalization in order to compare extrahematological toxicity and supportive care, between the group of elderly autotransplanted patients (Ͼ60 years) and a control group of younger Bone Marrow Transplantation patients (Ͻ60 years). The log rank test was performed to compare hematological recovery between the two groups.
Overall survival was calculated from the day of transplant to death or last follow-up using the Kaplan-Meier method.
Results
Hematological toxicity and engraftment kinetics
All patients experienced severe pancytopenia requiring transfusion support (median: two platelet units and two packed red blood cell units (PRBC)) at a level comparable to that of younger patients autotransplanted in our center, as previously reported. The median time to PLT Ͼ20 ϫ 10 9 /l and Ͼ50 ϫ 10 9 /l was 13 (range: 9-83) and 17 days (range: 11-65), respectively. The median duration of hospital stay was 15 days (range: 11-61) starting from the day of PBPC reinfusion. The median duration of fever Ͼ38°C was 2 days (range: 0-29) and parenteral antibiotic therapy lasted a median of 7 days (range: 0-63). The number of CD34 + cells infused, transfusion need, hematological recovery, duration of severe neutropenia, fever, parenteral antibiotic therapy and hospital stay did not substantially differ from younger patients, as shown in Table 5 .
Extrahematological toxicity
As detailed in Table 6 , the extrahematological toxicity consisted mainly of severe infections in 24 patients (47.1%), Table 5 Comparison between the 48 elderly patients (Ͼ60 years) and the 208 young patients (Ͻ60 years) autotransplanted in the same period Table 7 . Only one patient died of pneumonia caused by Klebsiella pneumonia. We also registered three clinically documented cases of pneumonitis (7.3%).
In summary, we observed grade 3-4 (WHO) toxic episodes in 21.8% of cases and grade 1-2 toxicity in 78.2% of cases. The transplant-related mortality of the 55 transplant procedures was 1.8%.
We evaluated cardiac performance in 36 transplanted patients before and after HDT, by using a scintigraphic method, and left ventricular ejection fraction (LVEF) declined from 61 (range, 50-65) to 55 (range, 51-61), but the variation was not statistically significant. Respiratory function was evaluated before and after HDT in 25 patients by measuring FEV1, FVC, and the FEV1/FVC ratio and Six of these patients died from progressive disease before day +90.
COLD; no significant variations of respiratory volume were observed, while a small but significant reduction in COLD (from 94% to 81%) was observed.
To date we have not detected late engraftment failures or secondary myelodysplasia on regular hematological follow-up, and finally, no late extrahematological toxicities have been documented during clinical follow-up.
Clinical outcome and quality of life at day +90
Assuming that the intention to mobilize may sufficiently reflect the intention to transplant, we looked at the proportion of mobilization failures in patients aged more than 60 years. We recovered less than 2.5 ϫ 10 6 /kg CD34 + cells in seven out of 67 mobilization procedures in 49 patients. However, in six out of these seven cases, subsequent mobilizations allowed recovery of a total dose of CD34 + cells sufficient to perform an autologous PBPCT (Ͼ2.5 ϫ 10 6 /kg); the autotransplant was therefore feasible in 47 out of 48 patients (98%).
Among the 48 patients evaluable for outcome after transplantation, 16 (31.8%) died from disease progression, only one died from toxicity related to the transplant (1.8%) and 31 (68.1%) are still alive with a median follow-up of 37 months (range 1-67); follow-up after day +90 and the posttransplant status are detailed in Table 8 . Twelve patients relapsed, 16 experienced disease progression, five had stable disease and 14 are still in continuous CR with a median follow-up of 22 (1-67) months.
The overall survival (OS) in 48 evaluable patients is shown in Figure 1 . The curve does not show any plateau and it decreases very rapidly in the first 3 months after transplant. This is probably due to pre-transplant status since a small number of patients were in 1st CR before HDT (35.4%) while the others received HDT as salvage treatment, 10.4% of whom had PD. The QLQ-C30 symptoms scale evaluated at day +90, showed that fatigue and nausea were the most common symptoms but that they remained at an acceptable level (median score: 20 and 15 respectively). The median scores of other symptoms (pain, dyspnea, sleeplessness, appetite loss, constipation, diarrhea) and financial impact were all below 15. Figure 2 shows the evaluation of the functional scales. In this case a higher score corresponds to better function and the high scores observed (median scores: 60 for the social score and 70 for all the remaining scales) confirm the good quality of life of this subset of patients.
Discussion
In Europe, the proportion of elderly individuals (Ͼ60 years) is rapidly increasing and it is estimated that, by 2020, the population of over 60s will by far outnumber people under 20 years of age. Continuous aging of the world population and prolongation of the median duration of life are changing the 'treatment philosophy' in the elderly, since watch and wait and low-dose regimens no longer represent the only available options for elderly patients with potentially 'curable' hematological malignancies.
The elderly population is a heterogeneous group in which co-morbidities can play the pivotal role in tailoring chemotherapy; therefore pre-treatment evaluation of physical and psychological health in the elderly is critical for treatmentrelated decisions and is often difficult to perform. Moreover, very few clinical trials of cancer chemotherapy have included, until now, people under 60 or 65 years of age. 23 In the setting of hematological malignancies the efficacy of HDT in prolonging OS has been demonstrated only in trials including people under 60 years of age.
In our single center experience, we transplanted 48 patients with different hematological malignancies, but the main subsets are represented by patients with MM and lym- Bone Marrow Transplantation phoma, but also with ANLL. The main end point of our study was not to evaluate the outcome of patients, but the feasibility of HDT in this group of patients because to date only three studies have been published analyzing a total of 46 patients aged over 60 years. [24] [25] [26] However, there are many reports concerning autotransplantation in patients older than 50 years with different diseases. Some reports suggest the importance of age Ͼ50 years on TRM (LANL, EBMT), but others 27 suggest that age is not relevant to outcome after transplantation. In this study a very large number of elderly patients with multiple myeloma were included, but large studies concerning different subsets of elderly patients with other hematological diseases, potentially curable with HDT are lacking; moreover in the Siegel experience 27 the only conditoning regimens used were HD melphalan or melphalan plus TBI. When HDT is considered as a unique treatment opportunity or when this approach is considered as first choice for younger patients, concern about increased TRM in patients over 60 or 70 years could substantially preclude a favorable clinical outcome. However, in our single center experience over 6 years, we observed a very low (1.8%) TRM in these patients.
In our study, we selected only those patients characterized by good performance status for HDT without establishing a cut-off of age.
Since 1998 we have also considered a LVEF Ͻ50% as criterion for excluding patients from HDT procedure.
Forty-nine patients were considered as eligible for HDT and 48 of these provided a dose of CD34 + cells (у2.5 ϫ 10 6 /kg) sufficient to perform an autotransplant (98%). This percentage may estimate HDT feasibility in our elderly cohort.
Conditioning regimens were characterized by the inclusion of HDM in 50/55 procedures while only three patients received Bu-Cy and two TBI. This choice was due to the very low extrahematological toxicity of HDM 28 even if the incidence of mucositis and of severe infections still remain relevant during the aplastic phase. On the contrary, no other extrahematological major toxicities were documented and we did not observe significant impairment of cardiac and respiratory function after HDT. Also, hospital stay and the kinetics of engraftment seem to be comparable to those reported in younger patients. 22 Finally, neither performance status nor quality of life were substantially impaired after transplantation.
Age and performance status are the most important factors which can impair or reduce the use (or the efficacy) of HDT because of the very high extrahematological toxicity due to escalated doses of many drugs used in HDT conditioning regimens.
Age is also the most important prognostic factor in NHL 29 and it has been demonstrated that elderly patients have a lower CR rate and shorter survival, due to reduced drug doses and increased toxicity from chemotherapy. 30 In MM the use of HDT has often been limited by patient age and in ANLL prognosis of the elderly is very poor due both to the very high CHT-related toxicity and to the very high frequency of refractory diseases and relapse.
We looked at the post-transplant outcome in both our elderly and younger patients and we found that the younger patients (Ͻ60 years) had a better outcome in terms of CR rate (data not shown). Obviously, multicenter prospective randomized studies considering elderly patients stratified for hematological malignancies are warranted in order to establish HDT efficacy in comparison with conventional chemotherapy.
Our experience is a retrospective analysis performed to evaluate HDT efficacy and safety in elderly patients, and it can not therefore estimate the real impact of HDT in the management of hematological malignancies in elderly patients.
Our experience, including 33% of transplanted patients older than 65 years, suggests that not only standard chemotherapy, but also HDT treatment can usually be applied to older patients up to the age of 70-75 years who have no other major medical problems. 23 Pre-transplant status, ie disease chemosensitivity, probably affects response and survival after autologous PBSC transplant and this factor should be taken in account for a more optimum selection of elderly patients for HDT. Highdose therapy with autologous PBSC transplantation is now considered the standard treatment for chemosensitive relapse of IG-HG NHL 31 and first-line treatment in MM. 32 In ANLL the role of auto-transplantation is still being debated, 33, 34 but the very poor prognosis of ANLL in the elderly with conventional chemotherapy 35 requires alternative strategies such as HDT regimens with low extrahematological toxicity. 36 Finally, the observation that aging is associated with a decline in the functional reserve of many organs and changes in drug pharmacokinetics and pharmacodynamics requires the individualization of HDT schedules in this population in order to further optimize HDT in this ever increasing subset of patients. 37 
